Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
about
A "SMART" design for building individualized treatment sequencesBiomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewMethods for identification and confirmation of targeted subgroups in clinical trials: A systematic reviewAdaptive adjustment of the randomization ratio using historical control data.A Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and EthicsExploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.Predictive biomarker validation in practice: lessons from real trials.The BATTLE trial: personalizing therapy for lung cancer.Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.All-comers versus enrichment design strategy in phase II trials.Clinical trial designs for testing biomarker-based personalized therapies.Adaptive clinical trial designs in oncology.Evaluating many treatments and biomarkers in oncology: a new designAdvances in Statistical Approaches Oncology Drug Development.The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studiesDesign of clinical trials for biomarker research in oncology.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemDevelopment and use of integral assays in clinical trialsStudy designs and statistical analyses for biomarker researchAdaptive design of confirmatory trials: Advances and challenges.Bayesian clinical trials in actionClinical trial designs incorporating predictive biomarkers.From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.A review of phase II trial designs for initial marker validation.A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Genomic advances and their impact on clinical trial designClinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.Bayesian adaptive randomization designs for targeted agent development.Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.Phase II clinical trials in oncology: are we hitting the target?Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials.Translational research in oncology: key bottlenecks and new paradigms.Methodological and practical challenges for personalized cancer therapies.Integrating biomarkers in clinical trials.Statistical issues in the use of dynamic allocation methods for balancing baseline covariates.Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
P2860
Q24619631-8F22C6D0-7CB9-4B27-A01A-4E253CDC35CAQ26766584-745048AE-949F-4B7A-8E52-D9851CC5EDE9Q28086970-85B58BEC-43E2-4D9D-91EA-D839B6BE0D05Q30629562-F4E06B63-EEA1-437B-A774-32669E7191F7Q30977270-27D15C78-0D4C-43AC-A075-7B832B12C73FQ33923067-DBFA6C68-3BA2-4755-B00A-C43AC4F17342Q34032803-0B221FB8-7D34-43E1-AA09-03CA75C9BF5BQ34110168-99E6DAC8-E5C4-4247-884B-F52682ED642EQ34275011-044D9BF3-81CD-4DFC-A5B0-1C2011B02A14Q34535243-E4937B4B-CCBE-47E1-AEAA-3528287C718CQ34857268-A5BF9FF6-D25C-486C-A4FA-3864E6B8053BQ34977663-497B4704-84C8-496E-8888-463A7C227A7AQ35206844-4A76BF79-6F87-496A-B78C-44DBCBB7DC5EQ35379179-544EB124-359A-497A-B685-1EA35C7F8594Q35565672-E4CEFACF-04C8-4ACA-82E4-B50212E75320Q35693300-9387523B-DB26-47E2-9B3F-EFA71E5B4724Q35789708-04689A69-BB9C-4268-AA13-5841EA34DB0AQ35797280-EAD0455C-F711-4D5E-9B3B-EE97AD56F954Q35838558-44A195B0-6C8C-4241-9C3D-00A59FEB4C0AQ36239075-02EB5214-AC1B-4C62-9F65-47BAE8818A94Q36264856-28B91F0B-931C-45FB-8BD3-D80D4ECCD37BQ36392556-1A0868B7-3B5F-4807-9E21-30F3C51DDB1AQ36534713-3919FE71-A98A-45ED-946A-2BD4CFA3769BQ36615755-3F1B2327-28E9-4625-BC84-144A2B179CC7Q37188715-E6F97D25-765E-49A2-BA47-CF37516AADDDQ37220654-6B48ED4B-503E-4FA7-99A1-28C007DCC770Q37238720-A9639FBD-C3F2-4562-99C9-5DF674154D52Q37279699-25D1572A-6F31-4B31-9F56-60AAD6ADFE63Q37325013-DD9F3984-B2C7-4AFC-8B2C-1FE590C6823BQ37415504-D3C063EA-C9FB-407B-A2D3-5BAF23C89C50Q37416117-519ADC04-8410-45B8-8820-473DF453F8A3Q37583786-642027A2-FF08-42A3-B3C9-78B4C44F6FC4Q37705422-854E0DE0-020A-40F4-BCD2-651592FFC242Q37711677-91F365FB-615E-4EE7-B586-7927D4812F6BQ37734663-9CF7C159-4211-4EB0-AFDE-8D6B3461CC5EQ37798577-88E5F3DC-2364-4EB9-990D-AFF973C22BBDQ37848661-B75D2027-5B5B-4327-A1B0-50302460C282Q37853183-DB0E83CB-245A-46DA-A121-9CCE79A860CCQ38253744-7FEC5673-BAC3-4601-A04E-CD7E44099311Q38389980-A27ECFDF-FE9A-4C11-998C-D08B788FBC27
P2860
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Bayesian adaptive design for t ...... toward personalized medicine.
@ast
Bayesian adaptive design for t ...... toward personalized medicine.
@en
type
label
Bayesian adaptive design for t ...... toward personalized medicine.
@ast
Bayesian adaptive design for t ...... toward personalized medicine.
@en
prefLabel
Bayesian adaptive design for t ...... toward personalized medicine.
@ast
Bayesian adaptive design for t ...... toward personalized medicine.
@en
P2093
P2860
P356
P1433
P1476
Bayesian adaptive design for t ...... toward personalized medicine.
@en
P2093
Edward S Kim
J Jack Lee
P2860
P304
P356
10.1177/1740774508091815
P577
2008-01-01T00:00:00Z